India's 3-Year Glycine Dumping Probe Tests WTO Remedy Rules

For trade remedy practitioners, this investigation is a textbook exercise in WTO-compliant anti-dumping procedure: a domestic complainant alleges dumped imports cause material injury, and the DGTR must quantify the existence, degree, and effect of dumping over a defined investigation period. The outcome will turn on evidence from the 2022–25 window and whether the Finance Ministry accepts the DGTR's recommendation, making it a key precedent for India's use of anti-dumping measures against Chinese inputs.

India has opened a new front in its trade defence toolkit, with the Directorate General of Trade Remedies (DGTR) initiating an anti-dumping investigation into imports of Glycine from China on September 22, 2026. The move follows a complaint from domestic manufacturer Avid Organics, which alleges that dumped Chinese shipments are causing material injury to its operations. Glycine, a compound used both as a flavour enhancer and a pharmaceutical ingredient, becomes the latest product caught in India's widening net of anti-dumping probes against Chinese goods.

“

India has opened a new front in its trade defence toolkit, with the Directorate General of Trade Remedies (DGTR) initiating an anti-dumping investigation into imports of Glycine from China on September 22, 2026.

According to the DGTR notification reported by The Hindu and The Hindu BusinessLine, the authority will examine import data spanning 2022 to 2025 to determine the existence, degree, and effect of the alleged dumping. The procedural architecture matters: DGTR is the investigating body, but if it establishes dumping and injury, the final decision to impose duties rests with the Ministry of Finance. This division creates a two-stage review process that domestic producers and importers alike must navigate.

The case sits within broader geopolitical and industrial dynamics. The notification explicitly references U.S.-China trade tensions and China's significant industrial overcapacity as factors that pose a major risk of cheap Chinese goods being dumped in India. In recent months, India has launched multiple anti-dumping probes against Chinese products, responding to concerns that surplus production in China is finding its way into Indian markets at below-cost prices. Glycine, though relatively niche, is a critical input for pharmaceutical formulations and processed foods, which gives the investigation outsize importance for downstream supply chains.

For Avid Organics and other Indian glycine producers, a favourable outcome would deliver anti-dumping duties that could restore a level-playing field and protect domestic capacity. The complaint alleges material injury, suggesting that Chinese imports have undercut domestic prices and eroded market share. If the DGTR confirms dumping margins and injury over the 2022-25 period, the recommended duties could be substantial enough to shift procurement patterns. However, domestic production alone may not fully satisfy Indian demand, so importers and downstream manufacturers could face both higher costs and potential shortages during any transition.

The investigation is conducted under the multilateral framework of the World Trade Organization, of which both India and China are members. Anti-dumping duties are allowed when dumped imports cause or threaten material injury to a domestic industry. The DGTR's mandate is to ensure fair trading practices and create a level playing field, but the outcome will hinge on rigorous analysis of pricing data, production costs, and injury indicators over the three-year investigation window. For legal observers, the case illustrates how India is operationalizing its WTO rights while managing bilateral trade frictions.